Trial
NCT01010854
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of California, San Francisco
Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Condition
Breast Cancer
Intervention
VPA FEC100
Why stopped
Premature closure for lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-09